NCT06544928
Study on Home Obstructive Respiratory Exacerbations
Enrolling by Invitation
Not specifiedAges 40–80ObservationalStrados Labs, Inc.
~20 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:RESP™ Biosensor
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The study will assess observational outcome measures. No formal efficacy or safety endpoints are defined.
Measured over 12 months
Conditions
NCT06544928
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Jefferson Einstein Philadelphia Hospital
Philadelphia, Pennsylvaniano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Hospitalized for COPD exacerbation with plan for discharge within 48 hours OR
Visiting pulmonologist post COPD-exacerbation within 14 days of discharge from hospital 3. Tobacco History: Current or Former Smoker
Has smoked at least 100 cigarettes in his/her lifetime 4. Patient can follow study procedures, including instructions for self-placement and operation of biosensor
Patient has experience/owns a smartphone 5. Patient is accessible by telehealth/telephone for duration of the study 6. Patient is able and willing to return to study site for study visits as necessary
What this trial measures
- The study will assess observational outcome measures. No formal efficacy or safety endpoints are defined.12 months